ImpediMed Limited
IPD
Rank in Stocks
#29954
Operating as a medical software technology provider, ImpediMed Limited is... Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.
Share Price
$0.00273764
Last synced: 2026-11-12
Market Cap
$6.14M
Change (1 day)
-0.35%
Change (1 year)
-89.46%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ImpediMed Limited (IPD)
Category
Healthcare
P/S ratio for ImpediMed Limited (IPD)
P/S ratio as of November 2026 TTM: 1.00
According to ImpediMed Limited's latest financial reports and stock price, its current price-to-sales ratio (TTM) is 1.00. At the end of 2025 the company had a P/S ratio of 5.55.
P/S ratio history for ImpediMed Limited from 2007 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 1.00 | -81.92% |
| 2025 | 5.55 | -60.07% |
| 2024 | 13.91 | -51.31% |
| 2023 | 28.57 | 194.72% |
| 2022 | 9.69 | -35.44% |
| 2021 | 15.01 | 133.57% |
| 2020 | 6.43 | -39.42% |
| 2019 | 10.61 | -76.36% |
| 2018 | 44.89 | -8.52% |
| 2017 | 49.07 | -6.01% |
| 2016 | 52.20 | 8.96% |
| 2015 | 47.91 | 366.21% |
| 2014 | 10.28 | 72.20% |
| 2013 | 5.97 | -57.82% |
| 2012 | 14.15 | -34.12% |
| 2011 | 21.47 | 21.53% |
| 2010 | 17.67 | -6.89% |
| 2009 | 18.98 | -13.86% |
| 2008 | 22.03 | 0.00% |
| 2007 | 0.00 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 3.90 | 288.34% |
US
|
|
| 3.50 | 249.26% |
IE
|
|
| 4.48 | 346.64% |
US
|
|
| 3.05 | 203.98% |
US
|
|
| 9.23 | 819.84% |
US
|
Questions about ImpediMed Limited's P/S ratio
What is ImpediMed Limited's P/S ratio?
ImpediMed Limited's P/S ratio is 1.00, as of Nov 2026.
What was ImpediMed Limited's P/S ratio in 2025?
In 2025, ImpediMed Limited's P/S ratio was 5.55, compared with 13.91 in 2024.
How has ImpediMed Limited's P/S ratio changed since 2020?
From 2020 to 2025, ImpediMed Limited's P/S ratio was highest in 2023 (28.57) and lowest in 2025 (5.55).
How does ImpediMed Limited's P/S ratio compare with similar companies?
ImpediMed Limited's P/S ratio (1.00) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 9.23.